Amgen, J&J Barred From Marketing Procrit, Aranesp Chemo-Anemia Benefit

Amgen and Johnson & Johnson are no longer able to promote the impact of their respective erythropoiesis-stimulating agents Aranesp and Procrit on symptoms of anemia in cancer patients, FDA said